Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations

Pharmaceutical Research

Volumn 14, Issue 1, 1997, Pages 98-102

  Timmer, Cees J ^a   Paanakker, Jan E ^a   Vrijmoed De Vries, Maria ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Antidepressant; Mirtazapine; Org 3770; Pharmacokinetics; Remeron

Indexed keywords

MIRTAZAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BIOLOGICAL AVAILABILITY; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; HUMANS; MALE; MIANSERIN;

EID: 0031048167     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012067703764     Document Type: Article

References (15)

1. T. de Boer, F. Nefkens, and A. van Helvoirt. Eur. J. Pharmacol. 253:R5-6, 1994.
2. T. de Boer and G. S. F. Ruigt. CNS Drugs 4:(Suppl 1), 29-38, 1995.
3. C. de Montigny, N. Haddjeri, R. Mongeau, and P. Blier. CNS Drugs 4:(Suppl 1), 13-17, 1995.
4. G. Voortman and J. E. Paanakker. Human Psychopharmacol. 10:(Suppl 2), S83-96, 1995.
5. C. J. Timmer, A. Lohmann and C. P. A. Mink. Human Psychopharmacol. 10:(Suppl 2), S97-106, 1995.
6. C. J. Timmer, J. E. Paanakker and H. J. M. van Hal. Human Psychopharmacol., in press.
7. F. M. Kaspersen, A. A. M. van Rooij, E. G. M. Sperling, and J. H. Wieringa. J. Lab. Comp. Radiopharm. 27:1055-1068, 1989.
8. J. E. Paanakker and H. J. M. van Hal. J. Chromatogr. Biomed. Appl. 417:203-207, 1987.
9. U.S. Food and Drug Administration Guidance. Statistical procedures for bioequivalence testing using a standard two-treatment crossover design. Statement prepared by the Division of Bioequivalence, Office of Generic Drugs of the FDA, informal communication under 21 CFR 10.90, 1992.
10. Commission on the European Communities, Committee for Proprietary Medicinal Products CPMP. Note for Guidance, Investigation of Bioavailability and Bioequivalence, III/54/89-EN, 1991.
11. K. K. Midha, E. D. Ormsby, J. W. Hubbard, G. McKay, E. M. Hawes, L. Gavalas, and I. J. McGilveray. J. Pharm. Sci. 82:138-144, 1993.
12. D. J. Schuirmann. J. Pharmacokin. Biopharm. 15:657-680, 1987.
13. B. J. Winer. Statistical principles in experimental design, 2nd Ed., McGraw-Hill, New York, 1971, pp. 851-853.
14. H. P. Wijnand. Comp. Meth. Progr. Biomedicine 49:249-259, 1993.
15. SAS Institute Inc. SAS User's Guide. Version 5.16, SAS Institute Inc., Cary, N.C., U.S.A., 1987.